z-logo
Premium
Off‐Label Use of Drugs and Medical Devices: A Review of Policy Implications
Author(s) -
Stafford R S
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.22
Subject(s) - food and drug administration , clinical pharmacology , off label use , product (mathematics) , business , drug , medicine , pharmacology , health care , risk analysis (engineering) , political science , law , geometry , mathematics
“Off‐label use” occurs when the use of a medication or device deviates from what is mentioned in its US Food and Drug Administration (FDA) product label. Off‐label use is common, legal, and an important source of innovation; however, it can be costly, and strong evidence of the efficacy and safety of such use may be lacking. 1 Given the contradictory and unresolved expectations of major stakeholders, off‐label use remains problematic. It requires a new policy paradigm that can successfully balance the need for innovation against the imperatives of evidence‐based practice and finite health‐care resources. Clinical Pharmacology & Therapeutics (2012); 91 5, 920–925. doi: 10.1038/clpt.2012.22

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom